Neurent Medical news
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). The clearance gives clinicians access to an in-office treatment designed to create lesions to disrupt the posterior nasal nerves, for patients with chronic rhinitis.
Approximately one in four American
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. The hires bring deep medical device industry and ear, nose and throat-specific experience to the company that will support commercial advancement of Neurent’s proprietary NEUROMARK™ technology, an innovative in-office treatment for chronic rhinitis.
Key hir
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced it has closed a $25 million Series B financing. The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV. Fountain Healthcare Partners also participated as a returning investor with strong participation in the round.
The financing will support the exp
Neurent Medical`s rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues
LONDON, Nov. 13, 2018 /CNW/ -- Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises N
An Irish company developing a breakthrough therapy for a common nasal condition has raised €9.3 million.
Neurent Medical, based in Oranmore, Co Galway, is developing a